Vaporized mebufotenin leads to improvement in treatment‐resistant depression
The Brown University Psychopharmacology Update · 2026-08 · 37 (8) · 1-5
DOI: 10.1002/pu.31471 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Brown University Psychopharmacology Update, online erschienen am 28.06.2026.
Themen: Depression
Abstract (Originalsprache)
An individualized one‐day dosing regimen of a vaporized formulation of the psychedelic mebufotenin (5‐methoxy‐ N,N ‐dimethyltryptamine; 5‐MeO‐DMT) was more effective than placebo in improving depressive symptoms in adults with treatment‐resistant depression, a Phase 2b trial has found. No serious treatment‐emergent adverse events were reported during the 7‐day study. Results were published online March 2, 2026 in JAMA Psychiatry .
Zitieren
APA
(2026). Vaporized mebufotenin leads to improvement in treatment‐resistant depression. The Brown University Psychopharmacology Update, 37(8), 1-5. https://doi.org/10.1002/pu.31471
Vancouver
Vaporized mebufotenin leads to improvement in treatment‐resistant depression. The Brown University Psychopharmacology Update. 2026;37(8):1-5. doi:10.1002/pu.31471
BibTeX
@article{euvimed2026,
title = {Vaporized mebufotenin leads to improvement in treatment‐resistant depression},
journal = {The Brown University Psychopharmacology Update},
year = {2026},
volume = {37},
number = {8},
pages = {1--5},
doi = {10.1002/pu.31471}
}
EUVIMED